Cargando…
MYC dysregulation in the progression of multiple myeloma
Autores principales: | Misund, K, Keane, N, Stein, CK, Asmann, YW, Day, G, Welsh, S, Wier, SV, Riggs, D, Ahmann, G, Chesi, M, Viswanatha, D, Kumar, SK, Dispenzieri, A, Gonzalez-Calle, V, Kyle, RA, O’Dwyer, M, Rajkumar, SV, Kortüm, KM, Keats, J, Fonseca, R, Stewart, AK, Kuehl, WM, Braggio, E, Bergsagel, PL |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923575/ https://www.ncbi.nlm.nih.gov/pubmed/31439946 http://dx.doi.org/10.1038/s41375-019-0543-4 |
Ejemplares similares
-
Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014) -
The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias
por: Baughn, Linda B., et al.
Publicado: (2020) -
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
por: Kortuem, K M, et al.
Publicado: (2016) -
Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors
por: Demchenko, Yulia, et al.
Publicado: (2016) -
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019)